Annual FCF
-$155.03 M
-$19.55 M-14.43%
December 31, 2023
Summary
- As of February 7, 2025, BTAI annual free cash flow is -$155.03 million, with the most recent change of -$19.55 million (-14.43%) on December 31, 2023.
- During the last 3 years, BTAI annual FCF has fallen by -$88.36 million (-132.54%).
- BTAI annual FCF is now -11843.45% below its all-time high of -$1.30 million, reached on December 31, 2016.
Performance
BTAI Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$16.34 M
+$6.84 M+29.50%
September 30, 2024
Summary
- As of February 7, 2025, BTAI quarterly free cash flow is -$16.34 million, with the most recent change of +$6.84 million (+29.50%) on September 30, 2024.
- Over the past year, BTAI quarterly FCF has increased by +$10.53 million (+39.18%).
- BTAI quarterly FCF is now -4973.91% below its all-time high of -$322.00 thousand, reached on September 30, 2017.
Performance
BTAI Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$84.08 M
+$21.25 M+20.17%
September 30, 2024
Summary
- As of February 7, 2025, BTAI TTM free cash flow is -$84.08 million, with the most recent change of +$21.25 million (+20.17%) on September 30, 2024.
- Over the past year, BTAI TTM FCF has increased by +$70.94 million (+45.76%).
- BTAI TTM FCF is now -19408.35% below its all-time high of -$431.00 thousand, reached on March 31, 2017.
Performance
BTAI TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
BTAI Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.4% | +39.2% | +45.8% |
| 3 y3 years | -132.5% | +19.2% | -1.1% |
| 5 y5 years | -1019.4% | -117.0% | -200.6% |
BTAI Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -87.7% | at low | at high | +68.8% | -1.8% | +49.6% |
| 5 y | 5-year | -454.2% | at low | -106.3% | +68.8% | -200.6% | +49.6% |
| alltime | all time | <-9999.0% | at low | -4973.9% | +68.8% | <-9999.0% | +49.6% |
BioXcel Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$16.34 M(-29.5%) | -$84.08 M(-20.2%) |
| Jun 2024 | - | -$23.17 M(+30.9%) | -$105.33 M(-12.5%) |
| Mar 2024 | - | -$17.71 M(-34.1%) | -$120.38 M(-22.3%) |
| Dec 2023 | -$155.03 M(+14.4%) | -$26.86 M(-28.5%) | -$155.03 M(-7.1%) |
| Sep 2023 | - | -$37.58 M(-1.7%) | -$166.80 M(+4.0%) |
| Jun 2023 | - | -$38.23 M(-27.0%) | -$160.40 M(+3.3%) |
| Mar 2023 | - | -$52.35 M(+35.5%) | -$155.30 M(+14.6%) |
| Dec 2022 | -$135.48 M(+64.0%) | -$38.64 M(+23.9%) | -$135.48 M(+16.0%) |
| Sep 2022 | - | -$31.19 M(-5.8%) | -$116.78 M(+10.4%) |
| Jun 2022 | - | -$33.12 M(+1.8%) | -$105.81 M(+11.2%) |
| Mar 2022 | - | -$32.53 M(+63.1%) | -$95.17 M(+15.2%) |
| Dec 2021 | -$82.60 M(+23.9%) | -$19.94 M(-1.3%) | -$82.60 M(-0.7%) |
| Sep 2021 | - | -$20.22 M(-10.1%) | -$83.20 M(+1.4%) |
| Jun 2021 | - | -$22.48 M(+12.7%) | -$82.08 M(+10.2%) |
| Mar 2021 | - | -$19.96 M(-2.9%) | -$74.45 M(+11.7%) |
| Dec 2020 | -$66.67 M | -$20.54 M(+7.6%) | -$66.67 M(+23.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$19.10 M(+28.5%) | -$54.05 M(+27.2%) |
| Jun 2020 | - | -$14.86 M(+22.0%) | -$42.48 M(+25.4%) |
| Mar 2020 | - | -$12.17 M(+53.7%) | -$33.87 M(+21.1%) |
| Dec 2019 | -$27.97 M(+102.0%) | -$7.92 M(+5.2%) | -$27.97 M(+13.9%) |
| Sep 2019 | - | -$7.53 M(+20.4%) | -$24.55 M(+21.1%) |
| Jun 2019 | - | -$6.25 M(-0.3%) | -$20.27 M(+6.1%) |
| Mar 2019 | - | -$6.27 M(+39.4%) | -$19.11 M(+38.0%) |
| Dec 2018 | -$13.85 M(+530.6%) | -$4.50 M(+38.5%) | -$13.85 M(+32.6%) |
| Sep 2018 | - | -$3.25 M(-36.2%) | -$10.45 M(+38.9%) |
| Jun 2018 | - | -$5.09 M(+403.0%) | -$7.52 M(+170.9%) |
| Mar 2018 | - | -$1.01 M(-7.8%) | -$2.78 M(+26.5%) |
| Dec 2017 | -$2.20 M(+69.2%) | -$1.10 M(+241.0%) | -$2.20 M(+100.0%) |
| Sep 2017 | - | -$322.00 K(-6.7%) | -$1.10 M(+41.5%) |
| Jun 2017 | - | -$345.00 K(-20.0%) | -$776.00 K(+80.0%) |
| Mar 2017 | - | -$431.00 K | -$431.00 K |
| Dec 2016 | -$1.30 M | - | - |
FAQ
- What is BioXcel Therapeutics annual free cash flow?
- What is the all time high annual FCF for BioXcel Therapeutics?
- What is BioXcel Therapeutics annual FCF year-on-year change?
- What is BioXcel Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for BioXcel Therapeutics?
- What is BioXcel Therapeutics quarterly FCF year-on-year change?
- What is BioXcel Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for BioXcel Therapeutics?
- What is BioXcel Therapeutics TTM FCF year-on-year change?
What is BioXcel Therapeutics annual free cash flow?
The current annual FCF of BTAI is -$155.03 M
What is the all time high annual FCF for BioXcel Therapeutics?
BioXcel Therapeutics all-time high annual free cash flow is -$1.30 M
What is BioXcel Therapeutics annual FCF year-on-year change?
Over the past year, BTAI annual free cash flow has changed by -$19.55 M (-14.43%)
What is BioXcel Therapeutics quarterly free cash flow?
The current quarterly FCF of BTAI is -$16.34 M
What is the all time high quarterly FCF for BioXcel Therapeutics?
BioXcel Therapeutics all-time high quarterly free cash flow is -$322.00 K
What is BioXcel Therapeutics quarterly FCF year-on-year change?
Over the past year, BTAI quarterly free cash flow has changed by +$10.53 M (+39.18%)
What is BioXcel Therapeutics TTM free cash flow?
The current TTM FCF of BTAI is -$84.08 M
What is the all time high TTM FCF for BioXcel Therapeutics?
BioXcel Therapeutics all-time high TTM free cash flow is -$431.00 K
What is BioXcel Therapeutics TTM FCF year-on-year change?
Over the past year, BTAI TTM free cash flow has changed by +$70.94 M (+45.76%)